Literature DB >> 7560949

Congenital toxoplasmosis: prevention, screening and treatment.

R E Holliman1.   

Abstract

Congenital toxoplasmosis is an established cause of abortion, neonatal disease and ocular defects presenting in later life. Preventative options include health education, immunization and screening of pregnant women and infants with appropriate management of cases found to be at risk. Screening requires a knowledge of the disease, the test, the treatment and the administration of the proposed programme. Treatment can be directed towards the acutely infected mother, the infected fetus or infant and the patient with an acute exacerbation of ocular toxoplasmosis following congenital infection. Harm-benefit assessment of screening programmes designed to prevent congenital toxoplasmosis has produced conflicting results. Further research is required into the incidence of acute toxoplasmosis in pregnancy and subsequent congenital infection, the frequency of neonatal handicap, precise tests for the diagnosis of recent maternal infection and the presence of congenital toxoplasmosis and improved treatment of the infection.

Entities:  

Mesh:

Year:  1995        PMID: 7560949     DOI: 10.1016/0195-6701(95)90018-7

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  11 in total

1.  Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis.

Authors:  A J Cook; R E Gilbert; W Buffolano; J Zufferey; E Petersen; P A Jenum; W Foulon; A E Semprini; D T Dunn
Journal:  BMJ       Date:  2000-07-15

2.  Sero-epidemiology of toxoplasmosis amongst pregnant women in the greater accra region of ghana.

Authors:  I Ayi; S Aa Edu; K A Apea-Kubi; D Boamah; K M Bosompem; D Edoh
Journal:  Ghana Med J       Date:  2009-09

3.  A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection.

Authors:  T Scorza; S D'Souza; M Laloup; J Dewit; J De Braekeleer; H Verschueren; M Vercammen; K Huygen; E Jongert
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

Review 4.  Development of Toxoplasma gondii vaccine: A global challenge.

Authors:  Ramesh Verma; Pardeep Khanna
Journal:  Hum Vaccin Immunother       Date:  2012-10-30       Impact factor: 3.452

5.  Survey of obstetrician-gynecologists in the United States about toxoplasmosis.

Authors:  J L Jones; V J Dietz; M Power; A Lopez; M Wilson; T R Navin; R Gibbs; J Schulkin
Journal:  Infect Dis Obstet Gynecol       Date:  2001

Review 6.  Toxoplasmosis in Mexico: epidemiological situation in humans and animals.

Authors:  Ivonne Hernández-Cortazar; Karla Y Acosta-Viana; Antonio Ortega-Pacheco; Eugenia del S Guzman-Marin; Armando J Aguilar-Caballero; Matilde Jiménez-Coello
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Mar-Apr       Impact factor: 1.846

7.  A meta analysis on risks of adverse pregnancy outcomes in Toxoplasma gondii infection.

Authors:  Xue-Lan Li; Hai-Xia Wei; Hao Zhang; Hong-Juan Peng; David S Lindsay
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

8.  Toxoplasma gondii infections among pregnant women, children and HIV-seropositive persons in Accra, Ghana.

Authors:  Irene Ayi; Augustine Odoi-Kpoti Sowah; Emmanuel Awusah Blay; Takashi Suzuki; Nobuo Ohta; Patrick F Ayeh-Kumi
Journal:  Trop Med Health       Date:  2016-06-01

9.  The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis.

Authors:  Christine Binquet; Catherine Lejeune; Valérie Seror; François Peyron; Anne-Claire Bertaux; Olivier Scemama; Catherine Quantin; Sophie Béjean; Eileen Stillwaggon; Martine Wallon
Journal:  PLoS One       Date:  2019-09-18       Impact factor: 3.240

10.  Toxoplasma gondii Recombinant antigen AMA1: Diagnostic Utility of Protein Fragments for the Detection of IgG and IgM Antibodies.

Authors:  Bartłomiej Ferra; Lucyna Holec-Gąsior; Justyna Gatkowska; Bożena Dziadek; Katarzyna Dzitko
Journal:  Pathogens       Date:  2020-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.